Attana Diagnostics

AVA™ &
Generic diagnostic platform

Diagnostics

As a response to the COVID-19 pandemic, we developed and launched Attana Virus Analytics™ (AVA™) – our first diagnostic solution. The AVA™ platform consists of our Cell™ 250 instrument, consumables, protocols and training services, offering clinical labs a rapid path to gaining in-depth data from patient serum samples and the ability to create patient immunity profiles over time.

We have already commenced work on broadening our diagnostic portfolio with additional assays and are exploring the potential for a point-of-care device based on whole blood samples.

Attana is currently certified for the development and sales of life science analysis systems and associated consultancy services for research purposes. Attana is listed by the The Swedish Public Health Agency as a supplier of instruments for COVID-19 testing.

Attana Virus Analytics™

The next generation of virus intelligence

Comprehensive

Detailed patient classification based on superior methodology and analysis of antibody and virus metrics

Scalable

Scalable technology allowing for a wide range of commercial applications and large-scale testing

Patented

Streamlined technology used in research and drug development since 2005; patent and IP protected viral testing process

Attana Virus Analytics™ enables precise measurements of key metrics for assessing COVID-19 immunity

Development of Attana Diagnostics

2005-2020

Preclinical development

Early development of our technology to detect and categorize antibodies from human sera and blood

April 2020

Enabling novel COVID-19 findings

Prof. Salanti at CPH University measures SARS-CoV-2 IgG antibodies in vaccinated mice using Attana's instrument

June 2020

Preparing AVA for patient samples

Novel spike protein of SARS-CoV-2 delivered from ExpreS2ion Biotech and assay optimization is performed

June 2020

First testing of individuals using AVA

First human sera tests performed at Linnaeus University to validate accuracy and reproducibility. Successful detection of 16 individuals and in-depth antibody analyses are confirmed

Fall 2020

AVA proof of concept

AVA’s ability to detect and analyze 3 areas of the immune system response to SARS-CoV-2 is confirmed, proving potential for ground-breaking viral insights at scale

Spring 2021

Offering AVA to customers and further development

Large-scale testing of human sera and successful trials on whole blood. AVA now available for immediate delivery to COVID-19 testing and research labs

Our vision:
Immunity profiles providing insights in a broad range of areas from a single drop of blood

Interested in Attana Diagnostics?

We look forward to discussing how we can assist
with your diagnostic needs